

Information Governance

White Building
Littlemore Mental Health Centre
Sandford Road
Littlemore
Oxford
OX4 4XN

Tel: 0845 219 1269
Fax: 0845 219 1275
Web: www.oxfordhealth.nhs.uk

5 November 2018
Reference no. 18190260

Dear,

Request for Information: Freedom of Information Act

Thank you for your email of 11 October making a request for information under the Freedom of Information Act. You requested the following information and the Trust is able to provide the information below in response:

Request and Response:

- 1) Does your Trust have a policy on the use of unlicensed medicines? Please Answer Yes or No. If yes, please provide a copy of the policy and all other relevant documentation Yes
- 2) Does your Trust have a policy or protocol on obtaining informed consent from patients when an unlicensed medicine is used? Please answer Yes or No. If yes, please provide copies of all relevant documentation including copies of template informed consent materials used to consent patients where an unlicensed medicine is to be administered. Yes
- 3) Please state which Board level job role(s) is (are) responsible for patient safety and consenting. Director of Nursing / Medical Director
- 4) Does your Trust have, or intend to introduce, a policy that makes compounded bevacizumab routinely available to treat wet age-related macular degeneration? If yes please supply a copy of your policy. No – we don't use this medicine in OHFT
- 5) Does your Trust currently have a wholly NHS owned pharmacy with an aseptic unit for compounding/aliquotting medicines? Please answer Yes or NO. If yes, is this NHS pharmacy the same legal entity as that of your hospital Trust? No

6) Does your Trust currently host on its premises a privately owned pharmacy with an aseptic unit for compounding/aliquotting medicines? Please answer Yes or NO. If yes, please provide details of the third party provider of your pharmacy services. No

7) Over the past two years has your Trust, on more than one occasion, used compounded Avastin (bevacizumab) for ophthalmic use? Please answer Yes or No. No

If you answered yes to Q5 or Q6:

8) Is the pharmacy referred to above in Q5 or Q 6 currently providing, or potentially able to provide, compounded Avastin (bevacizumab) for ophthalmic use? Please answer Yes or No
N/A

9) Does the pharmacy referred to above in Q5 or Q6 currently hold an MHRA license for the manufacture of specials? Please answer Yes or No N/A

If you answered yes to Q5 or Q6 but no to Q9:

10) When was the pharmacy referred to above in answer to Q5 or Q6 last inspected by the CQC? N/A

If you answered no to questions Q5 or Q6 above, but yes to question Q7:

11) Please provide information regarding from whom your Trust has or obtained/purchased compounded Avastin (bevacizumab). If you cannot provide the name of any commercial supplier, please provide as much information as possible. N/A

If you are concerned with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to me and I will ensure the decision is reviewed. The Trust will consider undertaking a review if requested to do so within 40 working days of the date the response is received by the applicant, and will apply discretion if a longer period of time has passed.

Should you wish to make a complaint as a result of the outcome of such a review, you may apply directly to the Information Commissioner's Office (ICO) for a decision.

Generally, the ICO cannot make a decision unless you have exhausted the complaints procedure provided by the Trust for FoI Act matters.

The ICO can be contacted at:

The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF

Please contact me if there are any further queries.

Kind regards,

Yours sincerely,

Mark Underwood

Head of Information Governance